Core Viewpoint - Myriad Genetics, Inc. will hold its fourth quarter and full year 2024 earnings conference call on February 24, 2025, providing a financial overview and business update [1] Upcoming Investor Conferences - Management will participate in three upcoming investor healthcare conferences: - TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 9:50 am ET [4] - Raymond James 46th Annual Institutional Investors Conference on March 4, 2025, at 4:00 pm ET [4] - Leerink Global Healthcare Conference on March 10, 2025, at 2:20 pm ET [4] Company Overview - Myriad Genetics is a leader in genetic and genomic tumor testing and precision medicine, focusing on advancing health and well-being [3] - The company develops genetic tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [3]

Core Insights - Myriad Genetics, Inc. has entered an agreement to enhance education and access to hereditary cancer testing for CancerCARE for Life members, allowing over 1 million individuals to assess their eligibility for the MyRisk test [1][2] - The collaboration aims to strengthen Myriad's Hereditary Cancer testing business, which has been recognized for its significant advances in genomic medicine [2][3] Company Developments - Myriad Genetics' shares experienced a decline of 1.5% following the announcement of the collaboration [3] - The MyRisk Hereditary Cancer Test has been gaining synergies, and it was named one of the top 10 significant advances in genomic medicine by the American Journal of Human Genetics in December 2024 [3][4] - The company has a market capitalization of $1.13 billion and a long-term EPS growth rate of 44%, significantly higher than the industry average of 20% [4] Product Information - MyRisk with RiskScore is the first industry-leading hereditary cancer test that evaluates 48 genes associated with hereditary cancer risk for 11 different cancers [5] - The test provides a five-year and remaining lifetime breast cancer risk assessment when combined with family history and other clinical factors [5] Industry Outlook - The global hereditary cancer testing market was valued at $3.5 billion in 2021 and is projected to grow at a compound annual growth rate of 11.6% through 2031, driven by an increasing geriatric population and rising cancer incidence [8] - The collaboration with CancerCARE is expected to enhance market sentiment towards Myriad Genetics' stock [4] Additional Collaborations - In January, Myriad Genetics partnered with sports broadcaster Hannah Storm, who will serve as an ambassador for the Breast Cancer Risk Assessment Program [9]

Core Insights - Myriad Genetics, Inc. has partnered with INTERLINK Care Management to improve education and access to hereditary cancer testing for CancerCARE for Life members [1][4] - The agreement allows over one million individuals in CancerCARE's network to evaluate their eligibility for the MyRisk test through the MyGeneHistory quiz [2][3] Company Overview - Myriad Genetics is a leader in genetic and genomic tumor testing and precision medicine, focusing on advancing health and well-being through genetic insights [6] - The company offers the MyRisk with RiskScore Hereditary Cancer Test, which evaluates 48 genes linked to hereditary cancer risk and provides personalized risk assessments for various cancers [3][4] Industry Context - CancerCARE for Life is one of the largest cancer prevention and management programs in the U.S., combining education with personalized care to enhance member experiences [5] - The collaboration aims to increase access to genetic screening, enabling patients to make informed decisions regarding their health [4][5]

Core Insights - Myriad Genetics has received two new patents from the United States Patent and Trademark Office, enhancing its capabilities in bringing its tumor-informed, high-definition molecular residual disease (MRD) assay to market [1] - In 2024, Myriad was awarded three patents related to foundational MRD technology and cell-free DNA preparation methods, which enable highly sensitive and specific sequencing-based MRD assays [2] - The company emphasizes that its Precise MRD assay addresses critical questions in cancer treatment, specifically regarding treatment efficacy and cancer recurrence [3] Company Overview - Myriad Genetics is a leader in genetic and tumor genomic testing, focusing on precision medicine to improve health outcomes and reduce healthcare costs [5] - The Precise MRD test utilizes whole-genome sequencing to analyze hundreds to thousands of targeted variants, allowing for sensitive detection of low tumor levels [4] - The company is actively developing its Precise MRD assay in collaboration with academic partners and biopharma companies, with ongoing evaluations in high-impact studies [3][4] Patent Details - The newly issued patents include US patent No. 12,215,391, which pertains to automated methods of MRD analysis, and US patent No. 12,215,392, which relates to patient journey aspects of MRD [7]

Core Insights - Myriad Genetics and Lumea Inc. have entered into a collaboration to integrate Myriad's molecular diagnostic tests into Lumea's digital pathology platform, BxLink™ [1][2] Company Overview - Myriad Genetics specializes in genetic and genomic tumor testing and precision medicine, focusing on improving health and well-being through advanced genetic tests [5] - Lumea is a leader in clinical digital pathology, known for its innovative tissue-handling technology and AI-driven workflows, enhancing efficiency and quality in cancer diagnostics [4] Collaboration Details - The integration will allow healthcare providers to electronically order and track Prolaris and MyRisk tests, aiming to deliver results in under 10 days after specimen collection [2][3] - This collaboration is expected to reduce manual processes, thereby minimizing errors and improving the workflow for clinicians [2][3] Clinical Impact - Prolaris and MyRisk tests provide critical insights for cancer treatment decisions, with Prolaris quantifying prostate cancer aggressiveness and MyRisk evaluating hereditary cancer risk [3] - The integration is designed to empower patients and providers by delivering timely, precision-based insights that can lead to advanced treatment options and improved patient outcomes [3]

Core Insights - Myriad Genetics announced groundbreaking research on prenatal cell-free DNA screening at the Society for Maternal-Fetal Medicine Conference, highlighting the ability to conduct reliable tests as early as eight weeks of gestation [1][2] - The study received the Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics, showcasing the significance of the findings in the field of prenatal genetic screening [1] Study Findings - The Prequel Prenatal Screen with AMPLIFY™ technology allows for accurate results at eight weeks of gestation, with an average fetal fraction (FF) of 12.5% and a no-call rate of less than 0.5% [1][3] - The study involved a multi-site approach where subjects provided samples at different gestational ages, confirming that the Prequel with AMPLIFY can deliver reliable results comparable to typical cfDNA screening at 10 weeks or later [3] Clinical Implications - The ability to assess risks for chromosomal disorders at eight weeks is a significant advancement, enabling earlier diagnostic testing options for patients, such as chorionic villus sampling at 10 weeks instead of the typical 15 weeks for amniocentesis [2] - This advancement empowers clinicians and patients to make informed decisions regarding prenatal care [2] Technology Overview - Myriad's Prequel Prenatal Screen with AMPLIFY technology is the first prenatal cfDNA screen available at eight weeks, increasing fetal fraction by an average of 2.3-fold [5] - The test assesses risks for various chromosomal conditions, including Down syndrome, Edwards syndrome, Patau syndrome, and sex chromosome abnormalities [5] Additional Presentations - Myriad Genetics will also present on detecting maternal mosaicism in fetal sex chromosome aneuploidy screening, aiming to improve positive predictive value (PPV) for sex chromosome anomalies [4]

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company's "Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation" study was awarded SMFM's "Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics." The study found that ...

Company Overview - Myriad Genetics, Inc. (MYGN) has launched a new educational website, Know More Sooner, aimed at providing comprehensive information about reproductive and prenatal genetic testing, which is expected to enhance the company's Prenatal business [1][5] - The company currently has a market capitalization of $937.2 million and has consistently surpassed earnings estimates in the past four quarters, with an average surprise of 247.73% [4] Stock Performance - Following the launch of the Know More Sooner website, MYGN shares increased by 3.9%, reaching $12.76 [2] - Over the past year, MYGN's shares have declined by 42.2%, in contrast to a 12.4% decline in the industry [10] Market Insights - A survey indicated that a majority of women expressed interest in prenatal screening once they understood the benefits of genetic testing, although 40% reported not being offered non-invasive prenatal testing (NIPT) [3] - The global non-invasive prenatal testing market was valued at $4.21 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.06% from 2024 to 2030, driven by increasing demand, collaborations, and improved reimbursement scenarios [7] Product Offerings - Myriad Genetics offers three genetic tests for pregnant individuals: the SneakPeek Gender Test, which predicts fetal sex with over 99% accuracy as early as six weeks; the Foresight Carrier Screen, which identifies risks for serious inherited conditions; and the Prequel Prenatal Screen, which assesses risks for various chromosomal conditions as early as eight weeks [6]

Core Insights - Myriad Genetics has launched a new educational website, "Know More Sooner," aimed at providing comprehensive information about reproductive and prenatal genetic testing [1][2] Group 1: Website Features and Purpose - The "Know More Sooner" website aims to educate users on the benefits of prenatal genetic testing, dispel myths, and provide guidance on screening locations and actions for high-risk results [2] - The site includes real-life patient stories to demonstrate how prenatal screening can assist parents in managing their pregnancies [2] Group 2: Survey Insights - A survey indicated that many women desire prenatal screening once they understand its benefits, yet 40% of respondents reported not being offered noninvasive prenatal testing (NIPT) [3] - The survey was conducted with 1,000 US-based individuals who identified as pregnant or recently pregnant [6] Group 3: Recommendations and Expert Opinions - The American College of Obstetricians and Gynecologists (ACOG) recommends that carrier and cfDNA screening be offered to all pregnant patients, regardless of ancestry, maternal age, or risk of chromosomal abnormalities [4] - Experts from Myriad Genetics emphasize the importance of understanding genetic testing benefits to help women make informed decisions during pregnancy [5] Group 4: Genetic Tests Offered - Myriad Genetics offers three genetic tests for pregnant individuals: - SneakPeek Gender Test, which predicts fetal sex as early as six weeks with over 99% accuracy [8] - Foresight Carrier Screen, identifying risks of passing down serious inherited conditions [8] - Prequel Prenatal Screen, assessing risks for various chromosomal conditions as early as eight weeks [8]

Core Insights - Myriad Genetics, Inc. announced a study showing that the use of an online screening tool and education significantly increased the completion rate of hereditary cancer testing among patients [1][2][3] Study Findings - The study evaluated the impact of MyGeneHistory®, an online patient screening tool, and a virtual education program on hereditary cancer testing completion rates [2][6] - Approximately 30% more patients were identified as meeting the guidelines for hereditary cancer testing (HCT) after implementing the online tool [8] - There was a 50% increase in the number of patients who met the guidelines and were offered HCT [8] - More than twice the number of patients completed HCT following the implementation of the new tools [8] Clinician Feedback - Clinicians reported increased confidence in administering hereditary cancer risk assessments, with 87% stating that the online screening and education tools helped them adhere to recommended standards of care [3] - Over 80% of providers believed the program assisted them in following ACOG guidelines for hereditary cancer risk assessment [3] Program Overview - Myriad's Breast Cancer Risk Assessment Program includes the MyRisk® with RiskScore® Hereditary Cancer Test and the MyGeneHistory online screening tool [5] - The program aims to improve patient access and education regarding genetic testing [4][5] Study Details - The study involved over 10,000 patients across five U.S. community obstetrics/gynecology practices, with an eight-week observation period followed by training on the online tools [6]